Neuronetics Stock Price, News & Analysis

Neuronetics (NASDAQ: STIM) announced its inclusion in the Russell 2000 Index effective June 28, 2021, following the annual Russell indexes reconstitution. This recognition is based on the company's market capitalization as of May 7. The Russell index membership enhances Neuronetics' visibility among investors and validates its efforts to create shareholder value through its NeuroStar Advanced Therapy System, aimed at improving mental health outcomes. Approximately $10.6 trillion in assets are benchmarked against Russell indexes, making this a significant milestone for the company.

Neuronetics, a leader in transcranial magnetic stimulation, will showcase real-world clinical data on NeuroStar Advanced Therapy for Mental Health at the Clinical TMS Society Annual Meeting in West Palm Beach, Florida, from June 10-12, 2021. Highlights include presentations on clinical outcomes from the NeuroStar Outcomes Registry, covering efficacy comparisons and treatment protocols. Neuronetics, as a Platinum Sponsor, aims to enhance awareness of TMS's benefits for major depressive disorder. With over 4 million treatment sessions delivered, the company continues to influence mental health treatment.

Neuronetics, a medical technology company listed on NASDAQ under the symbol STIM, will present at The JMP Securities Life Sciences Conference on June 17, 2021, at 10:00 AM ET. CEO Keith Sullivan and CFO Steve Furlong will lead the discussion. A live audio webcast will be available on the company's investor relations page, with an archive accessible for 90 days post-event. Neuronetics focuses on developing products like the NeuroStar® Advanced Therapy System, a TMS treatment approved by the FDA for major depressive disorder.

Neuronetics has appointed Todd Cushman as Vice President of Business Development, effective immediately. This strategic move aims to enhance the company's international strategy and commercial operations, particularly for its NeuroStar Advanced Therapy for treating Major Depressive Disorder. Cushman brings over 35 years of experience, having previously held leadership roles at Bioness, Medtronic, and Acumed. His expertise is expected to drive market innovation in mental health treatment.

Neuronetics, a medical technology company, announced participation at the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 9:40 AM ET. CEO Keith Sullivan and CFO Steve Furlong will present details about the company’s innovative products designed to enhance the lives of patients with psychiatric disorders. A live audio webcast will be available on the company’s investor relations page, with a replay accessible for 90 days. Neuronetics is known for its NeuroStar® Advanced Therapy System, FDA-cleared for treating major depressive disorder.

Neuronetics (NASDAQ: STIM) reported its Q1 2021 results with revenues of $12.3 million, up 7% from Q1 2020. U.S. treatment session revenue rose 18% to $9.6 million, while international revenue skyrocketed 63%. However, the sales of the NeuroStar system decreased by 32% year-over-year. The gross margin improved to 81.9%, and operating expenses decreased to $17 million. The company ended Q1 with $121.3 million in cash, up significantly from last year. The full-year guidance has been adjusted, expecting worldwide revenue between $59 million and $63 million.

Neuronetics, a medical technology company, announced its participation in the American Psychiatric Association’s Annual Meeting, held virtually from May 1-3, 2021. The company will present real-world clinical data on its NeuroStar Advanced Therapy for treating Major Depressive Disorder (MDD). Key presentations will cover outcomes from over 5,000 patients and the effectiveness of transcranial magnetic stimulation (TMS) in patients with MDD and comorbidities. Neuronetics continues to lead in depression treatment, having delivered 3.5 million treatments across more than 900 locations in the U.S.

MALVERN, Pa., April 20, 2021 – Neuronetics, a commercial-stage medical technology company, announced plans to release its first quarter financial results before market open on May 4, 2021. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time the same day. The call will be available via webcast on the company's investor relations website. Neuronetics specializes in products for psychiatric disorders, notably the NeuroStar® Advanced Therapy System, cleared by the FDA for treating major depressive disorder.